Retinoblastoma Treatment Market Set to Touch US$ 3.0 Billion by 2030, According to RationalStat Analysis
13 oct. 2023 06h04 HE
|
Rationalstat LLC
Wilmington, Delaware, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Global Retinoblastoma Treatment Market value is US$ 2.2 billion in 2023 and is predicted to rise at a substantial CAGR of 4.5% during the...
Global Vancomycin Market to Reach $555.5 Million by 2030
03 mai 2023 12h37 HE
|
ReportLinker
New York, May 03, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vancomycin Industry" - https://www.reportlinker.com/p06033216/?utm_source=GNW Food and fuel...
Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years: P&S Market Research
06 avr. 2018 01h30 HE
|
P&S Market Research
NEW YORK, April 06, 2018 (GLOBE NEWSWIRE) -- According to a new research report titled “Oral Mucositis Therapeutics Pipeline Analysis, 2017” published by P&S Market Research, Oral Mucositis...
Innovation Pharmaceuticals Brilacidin Meets Key Secondary Endpoint in Phase 2 Trial, Delays Onset of Severe Oral Mucositis (SOM); Latest Results Further Support Topline Data Showing Trial Met Primary Endpoint of Reducing Incidence of SOM
03 janv. 2018 07h00 HE
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented additional secondary endpoint...
Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial
27 déc. 2017 07h30 HE
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging...
Innovation Pharmaceuticals Completes Final Patient Visit in Phase 2b Study of Oral Prurisol for Psoriasis
21 déc. 2017 07h30 HE
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces all patient follow-up...
Innovation Pharmaceuticals Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase 2 Results and Increased Brilacidin Franchise Value
18 déc. 2017 07h30 HE
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today is pleased to provide an update on the...
Innovation Pharmaceuticals Granted European Patent for Brilacidin in the Prevention of Oral Mucositis
12 déc. 2017 08h00 HE
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the European Patent...
Innovation Pharmaceuticals Reports Positive Topline Results from Phase 2 Placebo-Controlled Trial of Brilacidin for the Prevention of Oral Mucositis in Head and Neck Cancer Patients; Company Targets a Therapeutic Leadership Position in Global OM Market
11 déc. 2017 07h00 HE
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented successful topline results...
Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2b Study of Oral Prurisol for Psoriasis
30 nov. 2017 08h00 HE
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has...